Complete set of polypeptide for predicting whether liver cancer is easy to relapse or not after being treated with ablation by using tumor antigen specific T cell reaction and application of complete set of polypeptide

A complete set of liver cancer technology, applied in the field of biomedicine, can solve the problems of high recurrence rate of HCC, loss of the best treatment period for liver cancer eradication, low early diagnosis rate, etc., and achieve the effect of good application prospects.

Inactive Publication Date: 2020-11-03
BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the lack of sensitive early diagnostic markers, once the liver cancer is discovered, it has reached the advanced stage, and the best treatment period for liver cancer eradication has been lost....

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Complete set of polypeptide for predicting whether liver cancer is easy to relapse or not after being treated with ablation by using tumor antigen specific T cell reaction and application of complete set of polypeptide
  • Complete set of polypeptide for predicting whether liver cancer is easy to relapse or not after being treated with ablation by using tumor antigen specific T cell reaction and application of complete set of polypeptide
  • Complete set of polypeptide for predicting whether liver cancer is easy to relapse or not after being treated with ablation by using tumor antigen specific T cell reaction and application of complete set of polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1, the preparation of complete polypeptide

[0045] This embodiment provides a set of polypeptides consisting of a set of polypeptides A and a set of polypeptides B, denoted as a set of polypeptides A+B. The set of polypeptides A consists of 27 polypeptides, as shown in Table 1, and the quality of each polypeptide in the set of polypeptides A is equal. The set of polypeptides B consists of 23 polypeptides, as shown in Table 2, and the quality of each polypeptide in the set of polypeptides B is equal.

[0046] Table 1. Set of peptides A

[0047] name Sequence (N-terminal-C-terminal) A1 MNGDDAFARRPTVGAQIP (sequence 1) A2 RRPTVGAQIPEKIQKAFD (sequence 2) A3 IPEKIQKAFDDIAKYFSK (sequence 3) A4 FDDIAKYFSKEEWEKMKA (Sequence 4) A5 SKEEWEKMKASEKIFYVY (Sequence 5) A6 KASEKIFYVYMKRKYEAM (Sequence 6) A7 VYMKRKYEAMTKLGFKAT (Sequence 7) A8 AMTKLGFKATLPPFMCNK (sequence 8) A9 ATLPPFMCNKRAEDFQGN (Sequence 9) ...

Embodiment 2

[0052] Example 2, the complete set of polypeptides in Example 1 can predict whether liver cancer is prone to recurrence after ablation

[0053] Objects: 58 patients diagnosed with hepatocellular carcinoma in Beijing You'an Hospital affiliated to Capital Medical University.

[0054] Hepatocellular carcinoma diagnostic criteria: Hepatocellular carcinoma was diagnosed with reference to my country's "Primary Liver Cancer Diagnosis and Treatment Standards (2017 Edition)".

[0055]The above 58 patients with hepatocellular carcinoma met the following conditions: Chinese liver cancer staging scheme Ia, Ib or IIa, and met PS0-2 points + ChildA-B level + no extrahepatic metastasis + no vascular invasion.

[0056] Peripheral blood mononuclear cells were extracted from the peripheral blood of each patient before operation.

[0057] Treatment: Liver cancer ablation is used, and the treatment is completed when the tumor is completely destroyed and an ablation margin of 0.5-1 cm appears.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a complete set of polypeptide for predicting whether liver cancer is easy to relapse or not after being treated with ablation by utilizing tumor antigen specific T cell reaction and an application of the complete set of polypeptide. The complete set of polypeptide disclosed by the invention consists of 50 polypeptides shown as sequences 1-50 in a sequence table. By detecting the reaction intensity of T cells in peripheral blood mononuclear cells of a patient suffering from liver cancer, before being treated by ablation on the complete set of polypeptide, the inventor finds that the reaction intensity of T cells in a relapsing group on the complete set of polypeptide is obviously higher than that of T cells in a non-relapsing group. Results show that the relapsing risk after ablation or prognosis can be predicted by detecting the response of tumor-associated antigen-specific T cells in peripheral blood mononuclear cells of a to-be-detected liver cancer patient tothe complete set of polypeptide, and the complete set of polypeptide has a good application prospect.

Description

technical field [0001] The invention relates to a set of polypeptides used in the field of biomedicine to predict whether liver cancer is likely to recur after ablation by using tumor antigen-specific T cell responses and an application thereof. Background technique [0002] Primary liver cancer is the third leading cause of death in China, and more than 85% to 90% of them are hepatocellular carcinoma (HCC). Due to the lack of sensitive early diagnostic markers, once the liver cancer is discovered, it is at an advanced stage, and the best treatment period for liver cancer eradication has been lost. In addition, even when patients are treated surgically, the recurrence rate of HCC is high. Therefore, the bottleneck of clinical diagnosis and treatment of HCC is: low early diagnosis rate and high recurrence rate. In recent years, with the development of relevant clinical trials, tumor immunotherapy has received more and more attention in the treatment of advanced HCC due to i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K7/08G01N33/68G01N33/574C12Q1/02
CPCC07K7/08G01N33/5047G01N33/57438G01N33/68
Inventor 覃岭臧超然赵艳张永宏
Owner BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap